References
- USFDA. 2021 Accessed 05 Sep 2021. Orange book: approved drug products with therapeutic equivalence evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm.
- Weiswasser ES, and Danzis SD. The Hatch-Waxman act: history, structure, and legacy. Antitrust LJ. 2003;71:585.
- Applications for FDA Approval to Market a New Drug. 2003. 68 F.R. 36675.
- Applications for FDA Approval to Market a New Drug. 2003. 68 F.R. 36680.
- Brown DG. Recent developments in US law: remedies and damages for improper patent listings in the FDA’s Orange Book. J commer biotechnol. 2003;9(3):199–208.
- Djung JF. Insufficient mechanisms for Orange Book corrections and the FDA’s ministerial role: a need for reform. Conn L Rev. 2014;47:229.
- USFDA. FDA responses to frequently asked questions on patents and exclusivity, question 19. [cited Jul 02, 2021]. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079031.htm.
- USFDA. Interim response to forest laboratories. 2011 Contract No.: Docket no. FDA-2011-A-0363-0008.
- AstraZeneca. Request for advisory opinion by AstraZeneca. 2006 Contract No.: Docket no. FDA-2006-A-0063.
- USFDA. 2013. Interim response to Novo Nordisk’s request for advisory opinion. Contract No.: Docket no. FDA-2012-A-1169.
- The Orange Book Transparency Act of 2020. 2021. (H. R. 1503).
- In Re Lantus direct purchaser antitrust litigation (No. 18-2086). Washington, D.C.: The United States Court of Appeals for the First Circuit; 2020.
- Lilly News Release. September 28 2015. Lilly and Sanofi reach settlement agreement in U.S. insulin glargine litigation. [cited 2021 Sept 20, 2021]. https://investor.lilly.com/news-releases/news-release-details/lilly-and-sanofi-reach-settlement-agreement-us-insulin-glargine